From: Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
AE rate
Exact 95% confidence interval
Probability of seeing at least one event
1%
(0.0%, 5.8%)
0.607
2%
(0.7%, 9.1%)
0.847
3%
(1.2%, 10.6%)
0.941
4%
0.978
5%
(1.8%, 12.1%)
0.992